Featured

Status

All Statuses
  • Withdrawn1

Health Topics

Any Category
Diseases
Pathological Conditions, Signs and Symptoms
Pathologic Processes
Clear Filters

Search Clinical Trials

1 Result
Withdrawn
A Study of Bevacizumab to Prevent Malignant Ascites
All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study. The primary …
Baylor Role: Lead Sponsor